Our study highlights the potential of NRG1, miR-382-5p and lncRNA Ftx as transformative biomarkers in distinguishing between MS and NMO, offering new avenues for more precise diagnostics and personalized treatments. The gene discussed is NRG1; the disease is myeloid sarcoma.